Jazz Pharmaceuticals to present 19 abstracts at SLEEP 2025 conference.
ByAinvest
Thursday, May 29, 2025 7:32 am ET1min read
ANSS--
The abstracts will showcase Phase 4 data evaluating the effectiveness of low-sodium oxybate, Xywav® (calcium, magnesium, potassium, and sodium oxybates) oral solution, in patients with narcolepsy and IH. Highlights include the first interim results from the open-label, single arm XYLO trial, which assesses ambulatory and office blood pressure changes in narcolepsy patients after switching from a twice-nightly high-sodium oxybate oral solution to low-sodium oxybate, Xywav. Additionally, the DUET trial will present novel results on multiple sleep parameters, including the first presentation of polysomnography (PSG) outcomes in adults with IH.
Jazz Pharmaceuticals' commitment to patient-centric care is evident in these presentations, which aim to advance the understanding and treatment of narcolepsy and IH. The company's leadership in sleep medicine is underscored by the extensive research being presented at SLEEP 2025. The abstracts are available online at sleepmeeting.org/abstract-supplements [1].
References:
[1] https://www.prnewswire.com/news-releases/jazz-pharmaceuticals-to-present-expansive-research-demonstrating-comprehensive-treatment-benefits-of-xywav-calcium-magnesium-potassium-and-sodium-oxybates-in-sleep-conditions-and-associated-comorbidities-at-sleep-2025-302467729.html
GWAV--
JAZZ--
• Jazz Pharmaceuticals to present 19 abstracts at SLEEP 2025 • 11 late-breaking abstracts showcase sleep medicine research • Phase 4 data evaluates Xywav effectiveness in narcolepsy and IH • First interim results from XYLO trial to be presented • Extensive research highlights Jazz's leadership in sleep medicine • Ongoing commitment to advancing narcolepsy and IH treatment • Abstracts to be presented at the Associated Professional Sleep Societies meeting
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) has announced that it will present a total of 19 abstracts at the SLEEP 2025 meeting, the 39th annual meeting of the Associated Professional Sleep Societies (APSS), scheduled from June 8-11, 2025, in Seattle. Among these, 11 are late-breaking abstracts that highlight the company's extensive research in sleep medicine, particularly in the treatment of narcolepsy and idiopathic hypersomnia (IH).The abstracts will showcase Phase 4 data evaluating the effectiveness of low-sodium oxybate, Xywav® (calcium, magnesium, potassium, and sodium oxybates) oral solution, in patients with narcolepsy and IH. Highlights include the first interim results from the open-label, single arm XYLO trial, which assesses ambulatory and office blood pressure changes in narcolepsy patients after switching from a twice-nightly high-sodium oxybate oral solution to low-sodium oxybate, Xywav. Additionally, the DUET trial will present novel results on multiple sleep parameters, including the first presentation of polysomnography (PSG) outcomes in adults with IH.
Jazz Pharmaceuticals' commitment to patient-centric care is evident in these presentations, which aim to advance the understanding and treatment of narcolepsy and IH. The company's leadership in sleep medicine is underscored by the extensive research being presented at SLEEP 2025. The abstracts are available online at sleepmeeting.org/abstract-supplements [1].
References:
[1] https://www.prnewswire.com/news-releases/jazz-pharmaceuticals-to-present-expansive-research-demonstrating-comprehensive-treatment-benefits-of-xywav-calcium-magnesium-potassium-and-sodium-oxybates-in-sleep-conditions-and-associated-comorbidities-at-sleep-2025-302467729.html
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet